Generic Name: cabozantinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Exelixis

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Cabometyx is a multikinase inhibitor approved for advanced kidney cancer (renal cell carcinoma) and previously treated liver cancer (hepatocellular carcinoma).

General Info

Cabometyx is a kinase inhibitor that blocks the action of several enzymes, including VEGFR, RET, ROS1 and KIT, that play a role in cancer cell growth and development of blood vessels that feed tumors.

The CABOSUN trial showed that Cabometyx slows disease progression in people with advanced kidney cancer not previously treated with targeted therapy. The CELESTIAL trial showed that Cabometyx improved progression-free survival and overall survivals in patients with liver cancer that was previously treated with Nexavar (sorafenib). Cabometyx was first approved in 2012.


Dosing Info:

Cabometyx is taken as a once-daily tablet. A capsule formulation of cabozantinib known as Cometriq is approved for different kinds of cancer and is not interchangeable with Cabometyx tablets.

Side Effects

Common side effects include diarrhea, fatigue, loss of appetite, nausea, vomiting, high blood pressure and hand-foot syndrome (palmar-plantar erythrodysesthesia), with redness, swelling and pain on the palms of the hands and soles of the feet. Potential serious side effects may include severe bleeding (hemorrhage), severe hypertension, blood clots, gastrointestinal perforation, osteonecrosis (bone death) of the jaw and slow wound healing. Cabometyx may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: January 14, 2019